natgillin/translations-raw huggingface dataset:
No overall differences in pharmacokinetics were observed between healthy elderly subjects and younger subjects (see section 4.2). 
Med zdravimi starejšimi bolniki in mlajšimi osebami niso v celoti gledano opazili nikakršnih razlik v farmakokinetiki (glejte poglavje 4.2).
This prevents incorporation of amino acid residues into elongating peptide chains. 
To prepreči vgradnjo aminokislinskih ostankov v podaljšujoče se peptidne verige.
The adverse reaction profile of tigecycline in these 58 subjects was generally consistent with that in adults, with the exception of nausea (48.3 %), vomiting (46.6 %) and elevated lipase in serum (6.9 %) which were seen at greater frequencies in children than in adults. 
Profil neželenih učinkov tigeciklina pri teh 58 preiskovancih je bil na splošno skladen s profilom pri odraslih, razen pri navzei (48,3 %), bruhanju (46,6 %) in zvišanju ravni lipaze v serumu (6,9 %), saj so se ti neželeni učinki pri otrocih pojavljali pogosteje kot pri odraslih.
Adverse reactions reported with tigecycline, including clinical trials and post-marketing experience, are tabulated below. 
Neželeni učinki, o katerih so poročali pri uporabi tigeciklina, vključno s kliničnimi preskušanji in izkušnjami v obdobju trženja, so navedeni v spodnji preglednici.
This in vitro information is consistent with the lack of effect of tigecycline on digoxin clearance noted in the in vivo drug interaction study described above (see section 4.5). 
Ta in vitro informacija je v skladu s pomanjkanjem učinka tigeciklina na očistek digoksina, opaženim v in vivo študiji medsebojnega delovanja zdravil, ki je opisana zgoraj (glejte poglavje 4.5).
Thus, 5 ml of reconstituted solution is equivalent to 50 mg of the active substance. 
Zato 5 ml rekonstituirane raztopine ustreza 50 mg učinkovine.
Children and adolescents (8 to 17 years of age) Tigecycline is only to be used to treat patients aged 8 years and older after consultation with a physician with appropriate experience in the management of infectious diseases. 
Tigeciklin se lahko uporablja samo za zdravljenje bolnikov, starih 8 let ali več, po posvetovanju z zdravnikom, ki ima ustrezne izkušnje z obravnavo okužb.
If you receive more Tygacil than you should 
Če ste prejeli večji odmerek zdravila Tygacil, kot bi smeli
mg/L and R  2 mg/L 
(^) mg/l in R > 2 mg/l
As it is known for tetracycline class antibiotics, tigecycline may also induce permanent dental defects (discolouration and enamel defects) and a delay in ossification processes in foetuses, exposed in utero during the last half of gestation, and in children under eight years of age due to the enrichment in tissues with a high calcium turnover and formation of calcium chelate complexes (see section 4.4). 
Kot je znano za antibiotike tetraciklinske skupine, lahko tudi tigeciklin povzroči trajne okvare zob (obarvanje in okvare sklenine) in zakasnitev zakostenevanja pri plodovih, ki so bili zdravilu izpostavljeni in utero v drugi polovici nosečnosti, in pri otrocih, mlajših od osem let, zaradi kopičenja v tkivih z velikim obratom kalcija in nastajanja kompleksov kalcijevega kelata (glejte poglavje 4.4).
The reconstituted solution should be yellow to orange in colour; if not, the solution should be discarded. 
Rekonstituirana raztopina mora biti rumene do oranžne barve; če raztopina ni take barve, jo morate zavreči.
Limited experience is also available in treating patients with concurrent bacteraemia (3.4 %). 
Na voljo je tudi malo izkušenj z zdravljenjem bolnikov s sočasno bakteriemijo (3,4 %).
After reconstitution, 1 ml contains 10 mg of tigecycline. 
Po rekonstituciji 1 ml vsebuje 10 mg tigeciklina.
Higher Cmax values than in adult patients were observed in several children in these studies. 
Pri več otrocih v omenjenih študijah so ugotovili večje vrednosti Cmax kot pri odraslih.
Significant differences in sepsis/septic shock with tigecycline (2.2 %) vs comparators (1.1 %) were observed. 
Opazili so pomembne razlike glede sepse/septičnega šoka med tigeciklinom (2,2 %) in primerjalnimi zdravili (1,1 %).
• Complicated infection of the skin and soft tissues (the tissue below the skin), excluding diabetic foot infections. 
• zapleteno okužbo kože in mehkih tkiv (tkiva pod kožo), razen okužb diabetičnega stopala
Overgrowth of non-susceptible organisms, including fungi (see section 4.4). 
Razraščanje neobčutljivih mikroorganizmov, vključno z glivicami (glejte poglavje 4.4).
• Poor or slow wound healing 
• slabo ali počasno celjenje ran
The total clearance of tigecycline is 24 L/h after intravenous infusion. 
Celotni očistek tigeciklina po intravenskem infundiranju je 24 l/h.
Clinical Cure, mITT Population 0.75 mg/kg 
Klinična ozdravitev, populacija mITT 0,75 mg/kg 1 mg/kg 1,25 mg/kg
• If you are suffering from diarrhoea before you are given Tygacil. 
• če imate drisko, še preden začnete prejemati zdravilo Tygacil.
When administered through a Y-site, compatibility of tigecycline diluted in sodium chloride 0.9 % for injection is demonstrated with the following medicinal products or diluents: amikacin, dobutamine, dopamine HCl, gentamicin, haloperidol, Lactated Ringer's, lidocaine HCl, metoclopramide, morphine, norepinephrine, piperacillin/tazobactam (EDTA formulation), potassium chloride, propofol, ranitidine HCl, theophylline, and tobramycin. 
Kompatibilnost tigeciklina, razredčenega z 0,9-odstotnim natrijevim kloridom za injiciranje, pri injiciranju v podaljšek Y so dokazali za naslednja zdravila in vehikle: amikacin, dobutamin, dopaminijev hidroklorid, gentamicin, haloperidol, Ringerjev laktat, lidokainijev hidroklorid, metoklopramid, morfin, noradrenalin, piperacilin/tazobaktam (pripravek z EDTA), kalijev klorid, propofol, ranitidinijev hidroklorid, teofilin in tobramicin.
Read the package leaflet before use for directions on reconstitution and dilution. 
Pred uporabo preberite priloženo navodilo, ki vsebuje navodila za rekonstitucijo in redčenje zdravila!
A patient developing impaired healing should be monitored for the detection of superinfection (see section 4.8). 
Bolnike, pri katerih se razvije slabše celjenje, je treba spremljati zaradi odkrivanja superinfekcije (glejte poglavje 4.8).
S  0.25 mg/L and R  0.5 mg/L Enterobacteriaceae S  1 
S  0,25 mg/l in R > 0,5 mg/l Enterobacteriaceae S  1
• Skin rash, which may lead to severe blistering and peeling of the skin (Stevens-Johnson 
• kožni izpuščaj, ki lahko vodi do mehurjev in luščenja kože (Stevens-Johnsonov sindrom)
Elderly No dosage adjustment is necessary in elderly patients (see section 5.2). 
Starejši bolniki Pri starejših bolnikih prilagajanje odmerka ni potrebno (glejte poglavje 5.2).
In clinical trials in cIAI, the most common type of infection in tigecycline-treated patients was complicated appendicitis (50.3 %), followed by other diagnoses less commonly reported such as complicated cholecystitis (9.6 %), perforation of intestine (9.6 %), intra-abdominal abscess (8.7 %), gastric or duodenal ulcer perforation (8.3 %), peritonitis (6.2 %) and complicated diverticulitis (6.0 %). 
V kliničnih preskušanjih pri cIAI je bila najpogostejša vrsta okužb pri bolnikih, zdravljenih s tigeciklinom, vnetje slepiča z zapleti (50,3 %), sledile so mu druge diagnoze, o katerih so redkeje poročali, na primer vnetje žolčnika z zapleti (9,6 %), perforacija črevesa (9,6 %), intraabdominalni absces (8,7 %), perforacija želodčne ali duodenalne razjede (8,3 %), peritonitis (6,2 %) in zapleti divertikulitisa (6,0 %).
Based on an in vitro study tigecycline is a P-gp substrate. 
Na podlagi in vitro študije je tigeciklin substrat P-gp.
However, since tigecycline may prolong both prothrombin time (PT) and activated partial thromboplastin time (aPTT), the relevant coagulation tests should be closely monitored when tigecycline is co-administered with anticoagulants (see section 4.4). 
Ker pa lahko tigeciklin podaljša tako protrombinski čas (PČ) kot aktivirani parcialni tromboplastinski čas, moramo skrbno spremljati zadevne koagulacijske teste, kadar dajemo tigeciklin sočasno z antikoagulanti (glejte poglavje 4.4).
C-tigecycline, radioactivity was well distributed to most tissues, with the highest overall exposure observed in bone marrow, salivary glands, thyroid gland, spleen, and kidney. 
C-tigeciklina, se je radioaktivnost dobro porazdelila v večino tkiv, pri čemer so največjo celotno izpostavljenost izmerili v kostnem mozgu, slinavkah, ščitnici, vranici in ledvici.
If you are concerned that you may have been given too much Tygacil, talk to your doctor or nurse immediately. 
Če vas skrbi, da ste morda prejeli prevelik odmerek zdravila Tygacil, se nemudoma pogovorite z zdravnikom ali medicinsko sestro.
Powder for solution for infusion 10 vials 
Prašek za raztopino za infundiranje 10 vial
In clinical trials in cSSTI, the most common type of infection in tigecycline treated-patients was cellulitis (58.6 %), followed by major abscesses (24.9 %). 
V kliničnih preskušanjih pri cSSTI je bila najpogostejša vrsta okužbe pri bolnikih, zdravljenih s tigeciklinom, flegmona (58,6 %), ki so ji sledili večji abscesi (24,9 %).
Results of animal studies indicate that tigecycline crosses the placenta and is found in foetal tissues. 
Rezultati študij na živalih kažejo, da tigeciklin prehaja skozi posteljico in ga najdemo v plodovih tkivih.
What Tygacil is and what it is used for What you need to know before you receive Tygacil How Tygacil is given 
Kaj je zdravilo Tygacil in za kaj ga uporabljamo Kaj morate vedeti, preden boste prejeli zdravilo Tygacil Kako uporabljati zdravilo Tygacil Možni neželeni učinki
• Complicated infection in the abdomen 
• zapleteno okužbo v trebuhu
There are no or limited amount of data from the use of tigecycline in pregnant women. 
Podatkov o uporabi tigeciklina pri nosečnicah ni oziroma so omejeni.
Therefore, clearance of tigecycline is not expected to be affected by active substances that inhibit or induce the activity of the CYP450 isoforms. 
Zato ni pričakovati, da bi učinkovine, ki zavirajo ali inducirajo aktivnost izoencimov CYP450, vplivale na očistek tigeciklina.
• Increases in liver enzymes, hyperbilirubinaemia (excess of bile pigment in the blood) 
• zvišana raven jetrnih encimov, hiperbilirubinemija (zvišana raven žolčnega barvila v krvi)
Glucuronidation and renal excretion of unchanged tigecycline are secondary routes. 
Glukuronidacija in izločanje nespremenjenega tigeciklina skozi ledvice sta manj pomembni poti.
Tygacil is indicated in adults and in children from the age of eight years for the treatment of the following infections (see sections 4.4 and 5.1): 
Zdravilo Tygacil je indicirano pri odraslih in otrocih, starih 8 let ali več, za zdravljenje naslednjih okužb (glejte poglavji 4.4. in 5.1):
The safety of tigecycline was also investigated in an open-label, ascending multi-dose PK study in 58 children aged 8 to 11 years with cSSTI (n=15), cIAI (n=24) or community-acquired pneumonia (n=19). 
Varnost tigeciklina so preučili tudi v odprti farmakokinetični študiji z večkratnim odmerjanjem s povečevanjem odmerka pri 58 otrocih, starih od 8 do 11 let, s cSSTI (n = 15), cIAI (n = 24) ali zunajbolnišnično pljučnico (n = 19).
Tygacil should not be used in children under 8 years of age due to the lack of safety and efficacy data in this age group and because tigecycline may be associated with permanent teeth discolouration (see sections 4.2 and 4.8). 
Zdravila Tygacil ne smemo uporabljati pri otrocih, mlajših od 8 let, zaradi pomanjkanja podatkov o varnosti in učinkovitosti v tej starostni skupini in ker je uporaba tigeciklina lahko povezana s trajnim obarvanjem zob (glejte poglavji 4.2 in 4.8).
Results of studies in rats with tigecycline have shown bone discolouration. 
Rezultati študij s tigeciklinom na podganah so pokazali obarvanje kosti.
Tigecycline did not affect mating or fertility in rats at exposures up to 4.7 times the human daily dose based on AUC. 
Tigeciklin ni vplival na parjenje ali plodnost pri podganah pri izpostavljenostih, ki so bile do 4,7-krat večje od dnevnega odmerka za ljudi na podlagi AUC.
In an open-label, ascending multiple-dose study, 39 children aged 8 to 11 years with cIAI or cSSTI were administered tigecycline (0.75, 1, or 1.25 mg/kg). 
V odprti študiji z večkratnim odmerjanjem s povečevanjem odmerka je 39 otrok, starih od 8 do 11 let, s cIAI ali cSSTI prejelo tigeciklin (0,75, 1 ali 1,25 mg/kg).
• Tell your doctor immediately if you develop severe abdominal pain, nausea, and vomiting. 
• takoj povejte zdravniku, če se vam razvijejo hude bolečine v trebuhu, slabost s siljenjem na bruhanje (navzea) in bruhanje.
There is limited evidence of the clinical efficacy of tigecycline against enterococci. 
Dokazov klinične učinkovitosti tigeciklina proti enterokokom je malo.
Overall, the primary route of elimination for tigecycline is biliary excretion of unchanged tigecycline. 
V celoti gledano je primarna pot odstranjevanja tigeciklina iz telesa izločanje nespremenjenega tigeciklina z žolčem.
Although hepatic failure may occur in patients treated with tigecycline due to the underlying conditions or concomitant medicinal products, a possible contribution of tigecycline should be considered (see section 4.8). 
Čeprav lahko pride do odpovedi jeter pri bolnikih, zdravljenih s tigeciklinom, zaradi osnovnih bolezni ali sočasnega prejemanja drugih zdravil, moramo upoštevati tudi možni prispevek tigeciklina (glejte poglavje 4.8).
Tygacil should not be used in children aged under 8 years because of teeth discolouration (see sections 4.4 and 5.1). 
Zdravila Tygacil se ne sme uporabljati pri otrocih, mlajših od 8 let, zaradi obarvanja zob (glejte poglavji 4.4 in 5.1).
It is not known if Tygacil passes into breast milk in humans. 
Ni znano, če zdravilo Tygacil pri ljudeh prehaja v materino mleko.
5 ml Type 1 clear glass vials fitted with grey butyl rubber stoppers and snap-off aluminium crimp seals. 
5-mililitrske steklene viale iz prozornega stekla tipa 1, zaprte z zamaškom iz sive butilne gume in aluminijasto zaporko.
Digoxin did not affect the pharmacokinetic profile of tigecycline. 
Digoksin ni vplival na farmakokinetični profil tigeciklina.
The Tygacil solution should be yellow to orange in colour after dissolving; if it is not, the solution should be discarded. 
Raztopina zdravila Tygacil mora biti po raztapljanju rumene do oranžne barve; če raztopina ni take barve, jo je treba zavreči.
Metabolism and nutrition disorders hypoglycaemia, hypoproteinaemia 
Presnovne in prehranske motnje hipoglikemija, hipoproteinemija
Patients hypersensitive to tetracycline class antibiotics may be hypersensitive to tigecycline. 
Bolniki, ki so preobčutljivi za antibiotike tetraciklinske skupine, so lahko preobčutljivi na tigeciklin.
How to store Tygacil 
Kako uporabljati zdravilo Tygacil
Tigecycline is vulnerable to chromosomally-encoded multi-drug efflux pumps of Proteeae and Pseudomonas aeruginosa. 
Tigeciklin je dovzeten za kromosomsko kodirane multimedikamentozne iztočne črpalke družine Proteeae in vrste Pseudomonas aeruginosa.
Co-administration of P-gp inhibitors (e.g., ketoconazole or cyclosporine) or P-gp inducers (e.g., rifampicin) could affect the pharmacokinetics of tigecycline. 
Sočasna uporaba inhibitorjev P-gp (npr. ketokonazola ali ciklosporina) ali induktorjev P-gp (npr. rifampicina) bi lahko vplivala na farmakokinetiko tigeciklina.
Glycylcycline class antibiotics are structurally similar to tetracycline class antibiotics. 
Antibiotiki glicilciklinske skupine so po zgradbi podobni antibiotikom tetraciklinske skupine.
Tigecycline is not removed in significant quantities by haemodialysis. 
Tigeciklin se s hemodializo ne odstrani v pomembnih količinah.
• Low blood sugar 
• znižana raven sladkorja v krvi
Co-administration of P-gp inhibitors (e.g., ketoconazole or cyclosporine) or P-gp inducers (e.g., rifampicin) could affect the pharmacokinetics of tigecycline (see section 5.2). 
Sočasna uporaba inhibitorjev P-gp (npr. ketokonazola ali ciklosporina) ali induktorjev P-gp (npr. rifampicina) bi lahko vplivala na farmakokinetiko tigeciklina (glejte poglavje 5.2).
Do not use Tygacil 
Ne uporabljajte zdravila Tygacil:
If a focus of infection other than cSSTI or cIAI is identified after initiation of tigecycline therapy consideration should be given to instituting alternative antibacterial therapy that has been demonstrated to be efficacious in the treatment of the specific type of infection(s) present. 
Če po začetku zdravljenja s tigeciklinom ugotovimo, da žarišče okužbe ni cSSTI oziroma cIAI, je treba razmisliti o uvedbi zdravljenja z drugim antibiotikom, ki je dokazano učinkovit pri zdravljenju specifične okužbe, ki je prisotna.
Warfarin did not affect the pharmacokinetic profile of tigecycline. 
Varfarin ni vplival na farmakokinetični profil tigeciklina.
Tigecycline may have adverse reactions similar to tetracycline class antibiotics. 
Tigeciklin lahko povzroča neželene učinke, ki so podobni kot pri antibiotikih tetraciklinske skupine.
Therefore, it is important to consider this diagnosis in patients who present with diarrhoea during or subsequent to the administration of any antibacterial agent (see section 4.8). 
Zato je pomembno, da pri bolnikih, ki med uporabo ali po uporabi kateregakoli protibakterijskega zdravila dobijo drisko, pomislimo na to diagnozo (glejte poglavje 4.8).
In clinical trials in cIAI patients, impaired healing of the surgical wound has been associated with superinfection. 
V kliničnih preskušanjih je bilo pri bolnikih s cIAI slabše celjenje kirurških ran povezano s superinfekcijo.
Dizziness may occur and this may have an effect on driving and use of machines (see section 4.8). 
Lahko se pojavi omotica, ki lahko vpliva na sposobnost vožnje in upravljanja strojev (glejte poglavje
How Tygacil is given in this leaflet) 
Kako uporabljati zdravilo Tygacil v tem navodilu za uporabo)
Uncommon side effects are (may affect up to 1 in 100 people): 
Občasni neželeni učinki so (pojavijo se lahko pri največ 1 od 100 bolnikov):
In Phase 3 and 4 cSSTI and cIAI clinical studies, infection-related serious adverse reactions were more frequently reported for subjects treated with tigecycline (7.1 %) vs comparators (5.3 %). 
V kliničnih študijah faze 3 in 4 so pri bolnikih s cSSTI ter cIAI, zdravljenih s tigeciklinom, pogosteje poročali o resnih neželenih učinkih, povezanih z okužbami (7,1 %) kot pri bolnikih, zdravljenih s primerjalnimi zdravili (5,3 %).
Cases of liver injury with a predominantly cholestatic pattern have been reported in patients receiving tigecycline treatment, including some cases of hepatic failure with a fatal outcome. 
Pri bolnikih, ki so prejemali zdravljenje s tigeciklinom, so poročali o primerih poškodb jeter s prevladujočim holestatičnim vzorcem, vključno z nekaterimi primeri odpovedi jeter s smrtnim izidom.
In female rats, there were no compound-related effects on ovaries or oestrus cycles at exposures up to 4.7 times the human daily dose based on AUC. 
Pri podganjih samicah ni bilo vpliva na ovarije ali cikle estrusa pri izpostavljenostih, ki so bile do 4,7-krat večje od dnevnega odmerka za ljudi na podlagi AUC.
Cross-resistance between tigecycline and minocycline-resistant isolates among the Enterobacteriaceae due to multi-drug resistance (MDR) efflux pumps has been shown. 
Pri družini Enterobacteriaceae so dokazali navzkrižno odpornost med izolati, odpornimi proti tigeciklinu in minociklinu, zaradi iztočnih črpalk z multimedikamentozno rezistenco (MDR).
Tigecycline may be associated with permanent tooth discolouration if used during tooth development (see section 4.4). 
Tigeciklin je lahko povezan s trajnim obarvanjem zob, če ga dajemo med razvojem zob (glejte poglavje 4.4).
Therefore, no dosage adjustment is necessary when tigecycline is administered with digoxin. 
Zato pri sočasni uporabi tigeciklina z digoksinom prilagajanje odmerjanja ni potrebno.
Storage after preparation 
Shranjevanje pripravljenega zdravila
It is unknown whether tigecycline/metabolites are excreted in human milk. 
Ni znano, ali se tigeciklin/presnovki izločajo v materino mleko.
The target AUC0-12h in adults after the recommended dose of 100 mg loading and 50 mg every 12 hours, was approximately 2500 ng•h/mL. 
Tarčna AUC0-12h pri odraslih po priporočenem 100 mg polnilnem odmerku in 50 mg nadaljnjih odmerkih vsakih 12 ur je bila približno 2.500 ng•h/ml.
However, polymicrobial intra-abdominal infections have shown to respond to treatment with tigecycline in clinical trials. 
Vendar se je pokazalo, da se v kliničnih preskušanjih polimikrobne intraabdominalne okužbe odzivajo na zdravljenje s tigeciklinom.
Gram-positive Aerobes 
Grampozitivni aerobi
Gastrointestinal disorders nausea, vomiting, diarrhoea abdominal pain, dyspepsia, anorexia acute pancreatitis (see section 4.4) 
Bolezni prebavil navzea, bruhanje, driska bolečina v trebuhu, dispepsija, anoreksija akutni pankreatitis (glejte poglavje 4.4)
C-labelled material recovered in urine and faeces, but a glucuronide, an N-acetyl metabolite and a tigecycline epimer were also present. 
C, ki so jo prestregli iz urina in blata, nespremenjeni tigeciklin, prisotni pa so bili tudi glukuronid, N-acetilni presnovek in tigeciklinov epimer.
Tigecycline may be associated with permanent tooth discolouration in humans if used during tooth development (see section 4.8). 
Tigeciklin je lahko povezan s trajnim obarvanjem zob pri ljudeh, če ga dajemo med razvojem zob (glejte poglavje 4.8).
In an open-label, single ascending dose PK study, the safety of tigecycline was investigated in 25 children aged 8 to 16 years who recently recovered from infections. 
Varnost tigeciklina so preučili v odprti farmakokinetični študiji s povečevanjem enkratnega odmerka pri 25 otrocih, starih od 8 do 16 let, kmalu po okrevanju po okužbi.
Thereafter, the solution should be immediately withdrawn from the vial and added to a 100 ml intravenous bag or other suitable infusion container in the hospital. 
Nato je treba raztopino takoj z brizgo posrkati iz viale in jo dodati 100-mililitrski vrečki za intravensko infundiranje ali kakšnemu drugemu primernemu infuzijskemu vsebniku v bolnišnici.
No dosage adjustment is warranted in patients with mild to moderate hepatic impairment (Child Pugh A and Child Pugh B). 
Pri bolnikih z blago do zmerno okvaro jeter prilagajanje odmerjanja ni potrebno (razreda A in B po Child-Pughovi lestvici).
The vial should be gently swirled until the medicine is dissolved. 
Vialo je treba nežno vrteti, dokler se zdravilo ne raztopi.
Pseudomembranous colitis which may range in severity from mild to life threatening (see section 4.4). 
Psevdomembranski kolitis, katerega stopnja izraženosti lahko sega od blagega do smrtno nevarnega (glejte poglavje 4.4).
• Vein irritations from the injection, including pain, inflammation, swelling and clotting 
• draženje vene zaradi injiciranja, ki vključuje bolečino, vnetje, oteklino in krvni strdek
Injection should be made with an infusion solution compatible with tigecycline and any other medicinal product(s) via this common line (see section 6.2) 
Injicirati morate z infuzijsko raztopino, ki je kompatibilna s tigeciklinom in morebitnim/-i drugim/-i zdravilom/-i, po tem skupnem kanalu (glejte poglavje 6.2).
Tigecycline should be preferably administered over a 60-minute length of infusion in paediatric patients (see section 4.4). 
Zaželeno je, da se tigeciklin pri pediatričnih bolnikih daje z infuzijo, ki traja 60 minut (glejte poglavje 4.4).
Nausea and vomiting are very common adverse reactions in children and adolescents (see section 4.8). 
Pri otrocih in mladostnikih sta zelo pogosta neželena učinka navzea in bruhanje (glejte poglavje 4.8).
Injection should be made with an infusion solution compatible with tigecycline and any other medicinal product(s) via this common line. 
Injicirati morate z infuzijsko raztopino, ki je kompatibilna s tigeciklinom in morebitnim/-i drugim/-i zdravilom/-i, po tem skupnem kanalu.
Antibiotic class effects 
Učinki zdravil iz skupine antibiotikov
These may be symptoms of acute pancreatitis (inflamed pancreas which may result in severe abdominal pain, nausea, and vomiting). 
To so lahko simptomi akutnega pankreatitisa (vnetje trebušne slinavke, ki se lahko kaže kot huda bolečina v trebuhu, navzea in bruhanje);